Curis completes FDA-requested enrollment for emavusertib; FY2022 net loss $56.7M

CURIS INC

Completed enrollment of 9 additional patients at 200mg BID for TakeAim Leukemia study ahead of schedule; expects data in Q2, FDA meeting in Q3 for partial clinical hold resolution.
Net loss for FY2022 was $56.7M ($0.61 per share) vs $45.4M ($0.50) in 2021; Q4 net loss $11.3M ($0.12) vs $13.6M ($0.15) in Q4 2021.
Revenue from Erivedge royalties was $10.2M in FY2022 vs $10.6M; cash and investments $85.6M as of Dec 31, 2022, expected to fund operations into 2025.
R&D expenses increased to $43.3M from $34.9M in FY2022; company focused resources on emavusertib development.
Board adopted amended bylaws including exclusive forum provision and enhanced stockholder nomination requirements; advance notice deadline for 2024 annual meeting changed.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CURIS INC reported full year ended December 31, 2022 vs full year ended December 31, 2021 results: revenue 10.2 million vs 10.6 million, net income net loss of 56.7 million vs net loss of 45.4 million, EPS 0.61 per share loss vs 0.50 per share loss.

Period: full year ended December 31, 2022 vs full year ended December 31, 2021
Revenue: 10.2 million vs 10.6 million
Net income: net loss of 56.7 million vs net loss of 45.4 million
EPS: 0.61 per share loss vs 0.50 per share loss
Result: reported results

Exact text from the filing

to a net loss of $13.6 million or $0.15 per share on both a basic and diluted basis, for the same period in 2021. Revenues, net for the year ended December 31, 2022, were $10.2 million as compared to $10.6 million for the same period in 2021. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CURIS INC reported fourth quarter ended December 31, 2022 vs fourth quarter ended December 31, 2021 results: revenue 2.9 million vs 3.1 million, net income net loss of 11.3 million vs net loss of 13.6 million, EPS 0.12 per share loss vs 0.15 per share loss.

Period: fourth quarter ended December 31, 2022 vs fourth quarter ended December 31, 2021
Revenue: 2.9 million vs 3.1 million
Net income: net loss of 11.3 million vs net loss of 13.6 million
EPS: 0.12 per share loss vs 0.15 per share loss
Result: reported results

Exact text from the filing

Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®. Revenues for the fourth quarters of 2022 and 2021 were $2.9 million and $3.1 million, respectively. Costs of royalties which relate to third-party university patent licensors in connection with Genentech and Roche's Erivedge net sales, for the

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CURIS INC: Amended and restated by-laws to eliminate stockholder list requirement at meetings, address remote meeting adjournment due to technical failure, add exclusive forum provision, revise advance notice deadlines and procedural mechanics for stockholder nominations and proposals, add emergency by-law pro (effective 2023-03-07).

Change: bylaw amendment
Effective: 2023-03-07

Exact text from the filing

On March 7, 2023, the board of directors (the “Board”) of the Company approved an amendment and restatement of the Company’s Amended and Restated By-Laws (as so amended and restated, the “Amended and Restated By-Laws”), effective immediately.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.